KeyMed Biosciences Inc

KeyMed Biosciences Inc has a liquidity risk profile that is currently rated as medium, with a debt-to-equity ratio of 0.28 and a current ratio of 2.9, indicating a moderate level of short-term liquidity. The company's cash and equivalents amount to 30,075,000 CNY, which is significantly lower than its long-term debt of 788,541,000 CNY, resulting in a negative net cash position. This suggests that the company may need to rely on external financing or asset sales to meet its long-term obligations. The company's profitability is currently negative, with a return on equity of -18.84% and a return on assets of -12.39%. These figures are below the typical thresholds for a healthy biotechnology firm, which often require positive returns to justify ongoing R&D investments. The operating loss of 503,141,000 CNY and a net loss of 522,641,000 CNY further underscore the company's financial challenges. KeyMed Biosciences Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks, such as regulatory changes or economic downturns in its primary operating region. The company's growth trajectory is currently constrained by its financial performance. While the company has a mean price target of 87.67 CNY from analysts, the negative operating and net income figures suggest that achieving this target may be challenging without significant operational improvements or external funding. The operating cash flow of -712,407,000 CNY and free cash flow of -761,050,000 CNY indicate that the company is not generating sufficient cash to sustain operations or fund growth initiatives. The risk assessment for KeyMed Biosciences Inc highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position is a key flag, indicating potential difficulties in meeting short-term obligations. However, the low dilution risk suggests that the company is not currently issuing a large number of new shares, which could otherwise dilute existing shareholders' equity. Recent events and disclosures indicate that KeyMed Biosciences Inc is under analyst scrutiny, with a mean recommendation of 1.50, which is a strong buy rating. The company has received five strong-buy and five buy ratings, with no hold ratings, suggesting that analysts are generally optimistic about its long-term prospects despite its current financial challenges.